丝裂霉素C (培养级),Mitomycin C (cell culture tested)

产品编号:Sigma-M4287| CAS NO:50-07-7| MDL NO:MFCD00078109| 分子式:C15H18N4O5| 分子量:334.33

Mitomycin C 是一种抗肿瘤类抗生素,通过阻断DNA合成抑制多种肿瘤细胞。Mitomycin C通过诱导DNA链间交联,物理性阻断DNA复制,重组和RNA转录。Mitomycin C增强TRAIL-诱导的HCT116 (p53-/-)结肠癌细胞的凋亡,并通过死亡受体不依赖于JNK的上调使耐TRAIL的结肠癌细胞HT-29对细胞因子敏感。Mitomycin C 还是一种 ADC 毒性分子 (ADC Cytotoxin),可以诱导凋亡 (Apoptosis) 作用。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Sigma-M4287
850.00 杭州 北京(现货)
Sigma-M4287
3550.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

产品名称丝裂霉素C (培养级)
英文名称Mitomycin C (cell culture tested)
CAS编号50-07-7
产品描述Mitomycin C 是一种抗肿瘤类抗生素,通过阻断DNA合成抑制多种肿瘤细胞。Mitomycin C通过诱导DNA链间交联,物理性阻断DNA复制,重组和RNA转录。Mitomycin C增强TRAIL-诱导的HCT116 (p53-/-)结肠癌细胞的凋亡,并通过死亡受体不依赖于JNK的上调使耐TRAIL的结肠癌细胞HT-29对细胞因子敏感。Mitomycin C 还是一种 ADC 毒性分子 (ADC Cytotoxin),可以诱导凋亡 (Apoptosis) 作用。
产品熔点360 °C
产品沸点532.0±60.0 °C at 760 mmHg
产品密度1.9±0.1 g/cm3
产品闪点275.5±32.9 °C
精确质量334.127716
PSA146.89000
LogP-0.27
外观性状暗蓝色灰色结晶粉末
蒸气压0.0±3.2 mmHg at 25°C
折射率1.828
溶解性soluble
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (149.55 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.9911 mL 14.9553 mL 29.9106 mL
5 mM 0.5982 mL 2.9911 mL 5.9821 mL
10 mM 0.2991 mL 1.4955 mL 2.9911 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (6.22 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (6.22 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液
  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (6.22 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (6.22 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
*以上所有助溶剂都可在西域网站选购。
靶点

DNA synthesis

体外研究

HCT116(p53 - / - )细胞对丝裂霉素C或单独的TRAIL最不敏感。然而,令人惊讶的是,用MMC和TRAIL的组合处理显着降低了细胞活力。尽管单独的丝裂霉素C和TRAIL是中等有效的,但丝裂霉素C显着增强TRAIL对抑制细胞增殖的作用。单独的丝裂霉素C和TRAIL处理分别诱导9.5%和35.0%的细胞凋亡。然而,用丝裂霉素C和TRAIL联合治疗可使细胞凋亡增加至66.6%。丝裂霉素C是一种细胞毒性化学治疗剂,以DNA交联形式引起DNA损伤以及各种DNA单加合物,已知可诱导p53 。

体内研究

每隔一天用丝裂霉素C(ip,1mg / kg)和TRAIL(iv,100μg)处理携带异种移植的HCT116(p53 - / - )结肠肿瘤和HT-29结肠肿瘤的小鼠。用联合治疗方案的10个连续周期治疗动物。联合疗法显着抑制肿瘤生长,并且不影响小鼠的体重,表明丝裂霉素C和TRAIL的治疗组合具有良好的耐受性并且在体内具有抗肿瘤活性。膀胱内丝裂霉素C滴注对体重有影响,这在正常,NaCl滴注或表阿霉素滴注的大鼠中未观察到。连续3次每周滴注1mg / mL丝裂霉素C几乎没有体重增加,而其他3组中的大鼠与MMC治疗的大鼠相比具有统计学上显着的体重增加。

细胞实验

使用结肠腺癌HCT116和HT-29人结肠癌细胞。 CellTiter-Glo发光细胞存活率测定用于测量细胞活力,其使用独特,稳定形式的荧光素酶来测量ATP作为活细胞的指示物,并且产生的发光信号与培养物中存在的活细胞数成比例。 。将细胞用丝裂霉素C(5μM)预处理12小时或24小时,然后暴露于不同浓度的TRAIL 12小时。加入等体积(100μL)的CellTiter-GloTM试剂,将溶液在轨道振荡器上轻轻混合2分钟。将混合物在室温下孵育10分钟以使发光信号稳定,然后使用Xenogen IVIS系统进行成像以定量细胞活力。

动物实验

小鼠通过腹膜内注射用丝裂霉素C(1mg / kg)处理4至6周龄的NCr裸小鼠24小时,然后静脉内施用一剂纯化的rhTRAIL(100μg)。作为阴性对照,以相同的治疗频率用盐水(载体)注射(ip和iv)小鼠的子集。动物连续治疗3周。使用肿瘤体积的卡尺测量每周监测肿瘤大小。大鼠年龄为13周的年轻成年雌性Wistar大鼠,中位体重为217 g(范围187至255),随机分为4组,每组10只,即没有滴注的正常组,0.9%NaCl或安慰剂组接受滴注化学治疗剂,丝裂霉素C(1mg / mL)组和表柔比星(1mg / mL)组的溶剂。

稳定性Stable. Incompatible with strong acids, strong bases, strong oxidizing agents.
储存条件

储存条件:    2-8°C       

运输方式:    冰袋运输,根据产品的不同,可能会有相应调整。

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


符号 GHS06 GHS08
GHS06, GHS08
信号词 Danger
危害声明 H300-H351
警示性声明 P201-P202-P280-P301 + P310 + P330-P308 + P313-P501
个人防护装备 Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
危害码 (欧洲) T:Toxic
风险声明 (欧洲) R25;R40
安全声明 (欧洲) S36/37-S45-S28A-S28
危险品运输编码 UN 3462 6.1/PG 2
WGK德国 3
RTECS号 CN0700000
包装等级 II
危险类别 6.1(a)
Name: Mitomycin C (Contains 2mg Mitomycin C and 48mg Sodium Chloride) Material Safety Data Sheet
Synonym: Ametycine
CAS: 50-07-7
Section 1 - Chemical Product MSDS Name:Mitomycin C (Contains 2mg Mitomycin C and 48mg Sodium Chloride) Material Safety Data Sheet
Synonym:Ametycine

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
50-07-7 Mitomycin C 4 200-008-6
Hazard Symbols: T
Risk Phrases: 25 33

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Toxic if swallowed. Danger of cumulative effects.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
Harmful if swallowed. May cause liver damage. May cause digestive tract disturbances. May cause bone marrow depression.
Inhalation:
May cause respiratory tract irritation. May cause effects similar to those described for ingestion. May cause pulmonary fibrosis and permanent damage.
Chronic:
May cause cancer according to animal studies. Chronic exposure may cause liver damage. Adverse reproductive effects have been reported in animals. Potential cancer hazard.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Do not induce vomiting. If victim is conscious and alert, give 2-4 cupfuls of milk or water. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Non-combustible, substance itself does not burn but may decompose upon heating to produce irritating, corrosive and/or toxic fumes.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam. Substance is noncombustible; use agent most appropriate to extinguish surrounding fire.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use only in a well-ventilated area. Minimize dust generation and accumulation. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Do not ingest or inhale.
Storage:
Do not store in direct sunlight. Keep container closed when not in use. Store in a cool, dry, well-ventilated area away from incompatible substances. Hormones and antibiotics room. Store below 40C.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate general or local exhaust ventilation to keep airborne concentrations below the permissible exposure limits.
Exposure Limits CAS# 50-07-7: CAS# 7647-14-5: Russia: 5 mg/m3 TWA Personal Protective Equipment Eyes: Wear safety glasses and chemical goggles if splashing is possible.
Skin:
Wear appropriate protective gloves and clothing to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: blue-violet
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: > 360 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: soluble
Specific Gravity/Density:
Molecular Formula: C15H18N4O5
Molecular Weight: 334.32

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, light, dust generation, excess heat, temperatures above 40C.
Incompatibilities with Other Materials:
Strong oxidizing agents - strong acids - strong bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 50-07-7: CN0700000 CAS# 7647-14-5: VZ4725000 LD50/LC50:
CAS# 50-07-7: Oral, mouse: LD50 = 23 mg/kg; Oral, rat: LD50 = 30 mg/kg.
CAS# 7647-14-5: Draize test, rabbit, eye: 100 mg Mild; Draize test, rabbit, eye: 100 mg/24H Moderate; Draize test, rabbit, eye: 10 mg Moderate; Draize test, rabbit, skin: 50 mg/24H Mild; Draize test, rabbit, skin: 500 mg/24H Mild; Inhalation, rat: LC50 = >42 gm/m3/1H; Oral, mouse: LD50 = 4 gm/kg; Oral, rat: LD50 = 3000 mg/kg; Skin, rabbit: LD50 = >10 gm/kg.
Carcinogenicity:
Mitomycin C - California: carcinogen, initial date 4/1/88 IARC: Group 2B carcinogen Sodium chloride - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: II
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: II
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: II
USA RQ: CAS# 50-07-7: 10 lb final RQ; 4.54 kg final RQ

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: T
Risk Phrases:
R 25 Toxic if swallowed.
R 33 Danger of cumulative effects.
Safety Phrases:
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 50-07-7: 3
CAS# 7647-14-5: 0
Canada
CAS# 50-07-7 is listed on Canada's NDSL List.
CAS# 7647-14-5 is listed on Canada's DSL List.
CAS# 50-07-7 is not listed on Canada's Ingredient Disclosure List.
CAS# 7647-14-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 50-07-7 is listed on the TSCA inventory.
CAS# 7647-14-5 is listed on the TSCA inventory.


SECTION 16 - ADDITIONAL INFORMATION
N/A

~10%

50-07-7结构式

50-07-7

文献:Kasai; Kono; Ikeda; Yoda; Hirayama Journal of Organic Chemistry, 1992 , vol. 57, # 26 p. 7296 - 7299

~81%

50-07-7结构式

50-07-7

文献:Arai, Hitoshi; Kasai, Masaji Journal of Organic Chemistry, 1993 , vol. 58, # 15 p. 4151 - 4152

~73%

50-07-7结构式

50-07-7

文献:Kasai; Kono; Ikeda; Yoda; Hirayama Journal of Organic Chemistry, 1992 , vol. 57, # 26 p. 7296 - 7299

~%

50-07-7结构式

50-07-7

文献:Kasai; Kono; Ikeda; Yoda; Hirayama Journal of Organic Chemistry, 1992 , vol. 57, # 26 p. 7296 - 7299

~79%

50-07-7结构式

50-07-7

文献:Furuhata; Komiyama; Takeda; Takayanagi; Torii; Mishima; Ogura; Hata Chemical and Pharmaceutical Bulletin, 1989 , vol. 37, # 10 p. 2651 - 2654

~20%

50-07-7结构式

50-07-7

详细
文献:Vyas, D. M.; Chiang, Y.; Benigni, D.; Doyle, T. W. Journal of Organic Chemistry, 1987 , vol. 52, # 25 p. 5601 - 5605

~%

50-07-7结构式

50-07-7

文献:Senter; Pearce; Greenfield Journal of Organic Chemistry, 1990 , vol. 55, # 9 p. 2975 - 2978

~%

50-07-7结构式

50-07-7

文献:Chen; Coppola; Johns; Bogardus; Lipper Journal of Pharmaceutical Sciences, 1986 , vol. 75, # 2 p. 208 - 210

~%

50-07-7结构式

50-07-7

文献:Danishefsky; Ciufolini Journal of the American Chemical Society, 1984 , vol. 106, # 21 p. 6424 - 6425

服务热线

13911702513
18601927057

微信客服